TrialThoracic cancer2020

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.

Ou Yamaguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.